Bal Pharma Limited has informed the Exchange regarding a press release dated September 28, 2021, titled "Bal Pharma poised to strengthen its position in diabetes segment through its Active Pharmaceutical ingredient ( API) Gliclazide.".
Bal Pharma Limited has informed the Exchange regarding a press release dated September 28, 2021, titled "Bal Pharma poised to strengthen its position in diabetes segment through its Active Pharmaceutical ingredient ( API) Gliclazide.".